RT Journal Article
SR Electronic
T1 Exclusive Enteral Nutrition Initiates Protective Microbiome Changes to Induce Remission in Pediatric Crohn’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.21.23300351
DO 10.1101/2023.12.21.23300351
A1 Häcker, Deborah
A1 Siebert, Kolja
A1 Smith, Byron J
A1 Köhler, Nikolai
A1 Heimes, Helena
A1 Metwaly, Amira
A1 Mahapatra, Aritra
A1 Hölz, Hannes
A1 De Zen, Federica
A1 Heetmeyer, Jeannine
A1 Socas, Katharina
A1 Le Thi, Giang
A1 Meng, Chen
A1 Kleigrewe, Karin
A1 Pauling, Josch K
A1 Neuhaus, Klaus
A1 List, Markus
A1 Pollard, Katherine S
A1 Schwerd, Tobias
A1 Haller, Dirk
YR 2023
UL http://medrxiv.org/content/early/2023/12/24/2023.12.21.23300351.abstract
AB Exclusive enteral nutrition (EEN) is the first-line therapy for pediatric Crohn’s disease (CD), but protective mechanisms remain unknown. We established a prospective pediatric cohort (n = 1271 fecal samples) to characterize the function of fecal microbiota and metabolite changes of treatment-naïve CD patients in response to EEN. Integrated multi-omics analysis identified network clusters from individually variable microbiome profiles, with Lachnospiraceae and medium chain fatty acids as protective features. Metagenomic analysis identified strain-level dynamics in response to EEN cessation, and 577 gene functions with significant changes in abundance. Functional changes of diet-exposed fecal microbiota were further validated in a combined approach using gut chemostat cultures and microbiota transfer into germ-free IL-10- deficient mice. EEN-like and fiber-rich dietary model conditions respectively prevented or induced IBD-like inflammation in gnotobiotic mice. Hence, we provide evidence that EEN therapy operates through explicit functional changes of temporally and individually variable microbiome profiles.Competing Interest StatementDHaller served on the Microbiome Expert Panel from Reckitt Benckiser Health Limited. TS received lecture honoraria from Nutricia and MSD and travel support from Abbvie and Ferring outside the submitted work.Clinical TrialGerman Clinical Trials Register accession No. DRKS00013306Funding StatementFunded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 395357507 (SFB 1371, Microbiome Signatures) and the Leona M. and Harry B. Helmsley Charitable Trust (project numbers 2847 and 2304-05970). TS is supported by the Medical & Clinician Scientist Program (MCSP) of the Faculty of Medicine at LMU Munich.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethics approval Ludwig-Maximilians University of Munich, approval No. 17-801I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes